CD30 expression (CD30-positive)

aka CD30-positive, CD30+, CD30 expression, CD30-expressing, CD30 IHC

CD30 is the antigen of Hodgkin Reed-Sternberg cells and anaplastic large cell lymphoma. Brentuximab vedotin is labelled for Hodgkin lymphoma without a CD30 test and for peripheral T-cell lymphomas that express it.

CD30 is read by immunohistochemistry; classical Hodgkin lymphoma and ALCL are uniformly positive, other T-cell lymphomas variably so. Brentuximab vedotin (Adcetris) is a CD30-directed antibody-drug conjugate labelled for classical Hodgkin lymphoma (first-line with chemotherapy, consolidation, relapsed), systemic ALCL and CD30-expressing peripheral T-cell lymphomas (ECHELON-2 required at least 10 percent of cells positive) and CD30-expressing mycosis fungoides or primary cutaneous ALCL. No numeric threshold appears in the indications.

Part ofCD30· TNFRSF8 All readouts

CD30: what it is and how drugs act on it · animated schematic, not to scale

Target · the protein and the cell it sits on
Drug · antibody, small molecule, cell or radioligand
Effect · signal, damage or kill

In plain words · CD30 is a protein on the malignant Reed-Sternberg cells of Hodgkin lymphoma and on some T-cell lymphomas, and the address for the ADC brentuximab vedotin.

IHC score 1 approval threshold

What it means for a patient

In Hodgkin lymphoma CD30 is taken as read and brentuximab vedotin is an option without further testing. In a T-cell lymphoma the pathologist reports whether the cells express CD30; if they do, brentuximab vedotin with chemotherapy is on label as first treatment.

Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.

Scoring rule

CD30 detected on tumour cells by immunohistochemistry; the Hodgkin indications assume it, the T-cell lymphoma indications say CD30-expressing without a percentage (ECHELON-2 used 10 percent or more).

“ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine”
ADCETRIS prescribing information

Thresholds used in approvals

Threshold	Drug	Cancer	Regulator	Source
CD30-expressing (no percentage in the label; ECHELON-2 used >= 10%) Adcetris indication for previously untreated systemic ALCL or other CD30-expressing peripheral T-cell lymphomas in combination with cyclophosphamide, doxorubicin and prednisone.	Brentuximab vedotin	Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)	FDA	label

Drugs whose label names it

Brentuximab vedotin

Trials that name this readout

Matched on the name and aliases of the readout in the title, setting and summary of each trial; a match is a mention, not proof the readout was an entry criterion.